

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01N 59/12, A61L 15/44	A1	(11) International Publication Number: WO 00/54593 (43) International Publication Date: 21 September 2000 (21.09.00)
<p>(21) International Application Number: PCT/EP00/02194</p> <p>(22) International Filing Date: 13 March 2000 (13.03.00)</p> <p>(30) Priority Data: 9905663.2 12 March 1999 (12.03.99) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): BRISTOL-MYERS SQUIBB COMPANY [US/US]; 345 Park Avenue, New York, NY 10154 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): PARSONS, Dave [GB/GB]; 6 Briar Drive, Heswell, Wirral L60 5RN (GB). JACQUES, Elizabeth [GB/GB]; 9 Cedar Grove, Hoole, Chester CH2 3LQ (GB). BOWLER, Philip [GB/GB]; 8 Woodbridge Close, Appleton, Warrington, Cheshire WA4 5RD (GB).</p> <p>(74) Agent: MAYS, Julie; Bristol-Myers Company Limited, Patent Dept., Swakeleys House, Milton Road, Ickenham, Uxbridge UB10 8NS (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: IODINE PREPARATION COMPOSITON</p> <p>(57) Abstract</p> <p>An iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer characterised in that the iodide is held separately from the oxidant until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 4.5 and pH 6 so that iodine is generated at a physiologically acceptable dose rate.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Iodine Preparation Composition

This invention relates to an antimicrobial composition which can be applied to wounds, cuts, abrasions or burns for the prevention or treatment of infections.

5 More particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing.

10 Topical antimicrobial materials and preparations containing them have long been recognised as important parts of antisepsis of intact skin and wounds. Iodine has been recognized as an antimicrobial agent with effectiveness against a wide range of micro-organisms. There are however several barriers to making an effective antimicrobial composition for application to wounds based on iodine. One problem is that iodine tends to react with organic materials found in the wound
15 other than the intended microbial targets. This means that to be effective, iodine needs to be included at high levels such as 0.9% by weight, as described in "Handbook of Wound Dressings" edited by Stephen Thomas, 1994 Journal of Wound Care. . At such levels and with continued use iodine may have undesirable local side effects such as cell toxicity, hypersensitivity reactions, skin
20 staining, and unpleasant odour and systemic adverse effects such as metabolic acidosis and impairment of renal function. For this reason application of iodine is recommended at levels below 1.35g in one week.

A further problem is that iodine has a relatively short shelf life when in aqueous solution meaning either that compositions which include water need to be freshly prepared before each application or again that iodine is included at high levels. These factors limit product form.

5

In the past these problems with iodine have sought to be addressed by the use of iodophors which act as a release mechanism for iodine. Iodophors are readily dissociable, loose complexes of iodine with polymers or surfactants. Iodophor compositions are not best suited to use on wounds because when applied to a wound, all iodine present in the composition is readily available for reaction and therefore the adverse reactions associated with high levels of iodine are not necessarily avoided.

10

There thus exists a need for a composition which delivers iodine to a wound at a rate which is high enough to provide effective antiseptis but which is low enough to avoid the problems of adverse reactions associated with high levels of iodine.

15

GB-B-2276546 to Diversey relates to improved iodophors which are prepared at the point of use. The composition comprises an iodide source, an oxidant and an acid source, the oxidant becoming active only when the composition is dissolved in an aqueous medium. The composition is said to overcome the stability problems associated with producing teat dip/spray iodine formulations for use in

20

the control of bovine mastitis. The rate of generation of iodine needed for these topical formulations for use on intact skin far exceeds that tolerable to a wound.

In these compositions such high levels of iodine are generated that a hydrotrope must be included to prevent the iodine from crystallising. In addition, iodine has a complex chemistry in aqueous solutions and exists in a number of equilibria. At high iodine concentrations in the presence of iodide there is a strong tendency for the tri-iodide ion to form. We believe that this ion has very little antimicrobial activity but can still be absorbed with the risk of systemic toxicity.

We have found that it is possible to prepare a composition which is capable of generating iodine at a rate and level that makes it suitable for use in wounds. This is achieved by separating certain of the ingredients and controlling the kinetics of the generation of iodine through the manipulation of pH.

Accordingly the present invention provides an iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer characterised in that the oxidant is held separately from the iodide until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 4.5 and pH 6 so that iodine is generated at a physiologically acceptable and efficacious rate.

The invention allows the preparation of compositions generating a low but effective iodine level for example up to about 2000 μ g per g of composition per

hour, preferably in the range of 5µg per g of composition per hour to 1500µg per g of composition per hour, more preferably in the range 50µg per g of composition per hour to 1000µg per g of composition per hour so that the amount of free iodine available for antiseptis at any time is at least 0.001%.

5

The compositions of the invention are preferably formulated to generate the above levels of iodine over a period of about 3 days.

10

The pH of the composition of the invention is generally below 5.8. We have found that if the pH is greater than about 6, the rate of production of iodine by reaction of the oxidising agent with iodide ions is too low to balance any losses of iodine by reaction with the organic matter. We have found that it is generally desired that the pH of the compositions is not below about 4.5 as otherwise there is a danger that the rate of oxidation of the iodide ions will be too fast with the result that the composition could become toxic.

15

20

The desired pH of the compositions may be achieved by incorporating buffering agents therein. Examples of buffering agents which may be included are citric acid/disodium hydrogen phosphate, citric acid/sodium citrate, acetic acid/sodium acetate. The buffering agent may conveniently be present in an amount of about 2% to 10%, preferably about 4% to 6% by weight and particularly about 5% by weight so as to provide an isotonic composition.

The amount of oxidant in the composition is tailored to provide a stoichiometric match with iodide. Preferably the oxidant is iodate and is provided in a molar ratio of 1:5 with iodide. In this way the iodide present in the composition fully

reacts with all the oxidant. To provide the levels and rate of production of iodine in the range described above it is desirable to include up to 2% by weight of iodide, preferably, from 0.2 % to 2 % by weight of iodide. Iodide and iodate are preferably present as sodium salts although other usual counter ions may be used.

Convenient forms of administration of the composition include aqueous gels, films, creams, tablets and capsules.

The following examples are illustrative of the present invention.

Example 1:

15

<u>Gel A</u>	<u>Weight g</u>
Hydroxyethyl cellulose	30.00
Propylene Glycol	150.00
Na ₂ HPO ₄	35.61
Citric Acid	21.01
Potassium Iodate	1.124
Water	762.256

20

25

Gel B

Weight in g

-6-

Hydroxyethyl cellulose	30.0
Propylene Glycol	150.0
Potassium Iodide	4.36
Water	815.64

5

Gel A was made by dissolving the buffer salt in a water/propylene glycol mix and then adding the iodate. When the solution is clear the hydroxyethyl cellulose is added and mixed until gelation is complete. Gel B was made by dissolving iodide in a water/propylene glycol mix. Hydroxyethyl cellulose was added to this mixture and mixed until gelation was complete.

The gels were packaged in separate syringes which were bound together with their nozzles fitted into a Y-shaped connector. The contents were sterilised by autoclaving at 121 C for 15 minutes. Simultaneous depression of the plungers allows the gels to be co-extruded and allows the gels to react while being dispensed into a wound. The co-extrusion of the gels results in a product producing approximately 100µg per g of composition per hour at a pH of about 5.4. The composition generated a greater than 5 log kill of *S. aureus* (NCIMB 9518) which is regarded as being an acceptable level of antimicrobial activity.

20

Example 2

Film A

g

-7-

	Hydroxypropylcellulose	16
--	------------------------	----

	Propylene Glycol	4
--	------------------	---

	Potassium Iodate	0.1124
--	------------------	--------

	Sodium phosphate	1.7805
--	------------------	--------

5.	Citric acid	1.0505
----	-------------	--------

	Water	77.0566
--	-------	---------

Film B

	Hydroxypropylcellulose	16
--	------------------------	----

10	Propylene Glycol	4
----	------------------	---

	Potassium Iodide	0.436
--	------------------	-------

	Water	79.564
--	-------	--------

15 The films are produced by knife over roller coating of aqueous solution onto an inert carrier followed by drying at a temperature not exceeding 100 C and sterilised by gamma irradiation.

The films may be cut into rectangles and added to a wound whereupon they dissolve in the wound fluid and reaction takes place.

Claims

1. An iodine preparation composition suitable for use on wounds comprising an iodide source, and oxidant and a buffer characterised in that the iodide is held separately from the oxidant until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 4.5 and pH 6 so that iodine is generated at a physiologically acceptable dose and rate.

2. An iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer for simultaneous or sequential use in the treatment of sepsis in wounds.

3. Use of an iodine preparation composition comprising an iodide source, an oxidant and a buffer for simultaneous or sequential use in the treatment of sepsis in wounds.

4. An iodine preparation composition as claimed in claim 1 characterised in that the composition is capable of generating from 5µg of iodine per g of composition per hour to 1500µg of iodine per g of composition per hour, preferably 100µg of iodine per g of composition per hour.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/02194

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A01N59/12 A61L15/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01N A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 99 65538 A (OXIBIO INC) 23 December 1999 (1999-12-23) abstract page 9, last paragraph page 11, paragraph 2 page 16, last paragraph -page 17, paragraph 2	1-4
X	US 5 128 136 A (BENTLEY J PETER ET AL) 7 July 1992 (1992-07-07) claims 6-9	1-4
X	GB 2 276 546 A (DIVERSEY CORP) 5 October 1994 (1994-10-05) cited in the application claims 1,2	1,2,4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

20 July 2000

Date of mailing of the international search report

28/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Decorte, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/02194

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 271 149 A (WINICOV MURRAY W ET AL) 2 June 1981 (1981-06-02) column 2, line 25 - line 54 column 1, line 65 -----	2
X	WO 95 12316 A (DUNCAN GROUP PLC ;KELEMEN MARY VIKTORIA (GB)) 11 May 1995 (1995-05-11) claim 12 -----	2

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/02194

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9965538	A	23-12-1999	AU 4699799 A	05-01-2000
US 5128136	A	07-07-1992	US 5081106 A	14-01-1992
			AU 8238391 A	18-02-1992
			WO 9201382 A	06-02-1992
GB 2276546	A	05-10-1994	AU 683040 B	30-10-1997
			AU 5905794 A	29-09-1994
			CA 2119918 A	27-09-1994
			FR 2702930 A	30-09-1994
			NZ 260178 A	26-03-1996
			US 5558881 A	24-09-1996
US 4271149	A	02-06-1981	AR 228578 A	30-03-1983
			AU 532821 B	13-10-1983
			AU 6205180 A	26-03-1981
			BE 885300 A	19-03-1981
			BR 8005961 A	31-03-1981
			CA 1127076 A	06-07-1982
			CH 645807 A	31-10-1984
			DE 3034290 A	02-04-1981
			DK 398080 A,B,	22-03-1981
			ES 495562 D	01-09-1981
			ES 8106757 A	16-11-1981
			FR 2465418 A	27-03-1981
			GB 2060385 A,B	07-05-1981
			IE 50792 B	23-07-1986
			IT 1220974 B	21-06-1990
			JP 1481594 C	27-02-1989
			JP 56099419 A	10-08-1981
			JP 63002242 B	18-01-1988
			MX 6446 E	31-05-1985
			NL 8005251 A,B,	24-03-1981
			NZ 194835 A	18-11-1983
			ZA 8005544 A	30-09-1981
WO 9512316	A	11-05-1995	AU 8001594 A	23-05-1995

